Sunshine Biopharma (SBFM) Gross Profit (2018 - 2026)

Sunshine Biopharma (SBFM) has reported Gross Profit for 9 consecutive years, with $2.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Gross Profit fell 29.1% year-over-year to $2.4 million; the trailing twelve-month figure through Jun 2026 stood at $10.7 million (down 11.58% YoY), and the FY2025 full-year result was $12.3 million, up 14.86% from the prior year.
• Gross Profit advanced to $2.4 million in Q2 2026 per SBFM's latest filing, from $2.2 million in the prior quarter.
• Across five years, Gross Profit topped out at $3.4 million in Q2 2025 and bottomed at $62800.0 in Q1 2022.
• Historically, Gross Profit has averaged $2.1 million across 5 years, with a median of $2.4 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Gross Profit surged 6157.61% in 2022, then fell 29.1% in 2026.
• Over 5 years, Gross Profit stood at $1.5 million in 2022, then soared by 72.22% to $2.6 million in 2023, then gained by 20.44% to $3.1 million in 2024, then dropped by 2.08% to $3.0 million in 2025, then retreated by 19.88% to $2.4 million in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $2.4 million, $2.2 million, and $3.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.